Glenmark's US recall of oral contraceptive unlikely to hurt revenues
This article was originally published in Scrip
Executive Summary
Glenmark Generics' voluntary recall of seven lots of its oral contraceptive, norgestimate and ethinyl estradiol tablets, in the US due to a packaging error is unlikely to have a significant impact on the firm's revenues, though consumer level recalls carry certain inherent risks, according to some analysts.